Nonclinical Models for Antituberculosis Drug Development: A Landscape Analysis

Journal of Infectious Diseases

Volumn 211, Issue , 2015, Pages S83-S95

  Gumbo, Tawanda ^a,b   Lenaerts, Anne J ^c   Hanna, Debra ^d   Romero, Klaus ^d   Nuermberger, Eric ^e  

^a BAYLOR RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Department of Environmental and Radiological Health Sciences   (United States)

^d CRITICAL PATH INSTITUTE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

antituberculosis; drug development; drug regimen design; Guinea pig tuberculosis model; hollow fiber system model of tuberculosis; mouse tuberculosis model

Indexed keywords

AMIKACIN; BEDAQUILINE; ETHAMBUTOL; ISONIAZID; METRONIDAZOLE; MOXIFLOXACIN; PRETOMANID; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT; DRUG COMBINATION;

AMBIENT AIR; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CLINICAL TRIAL (TOPIC); CONCENTRATION RESPONSE; DISEASE MODEL; DRUG EFFICACY; GUINEA PIG; HUMAN; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE MODEL; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RABBIT; RAT MODEL; STANDARDIZATION; TUBERCULOSIS; ANIMAL; DRUG COMBINATION; MICROBIOLOGY;

ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; HUMANS; TUBERCULOSIS;

EID: 84937458786     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv183     Document Type: Article

References (135)

1. Gumbo T, Angulo-Barturen I, Ferrer-Bazaga S. Pharmacokineticpharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia. J Infect Dis 2015; 211(suppl 3):S96-106.
2. Heifets LB. Antituberculosis drugs: Antimicrobial activity in vitro. In: Heifets LB, ed. Drug susceptibility in the chemotherapy of mycobacterial infections. 1st ed. Boca Raton, FL: CRC Press, 1991:13-57.
3. de Steenwinkel JE, de Knegt GJ, Ten Kate MT, et al. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J Antimicrob Chemother 2010; 65:2582-9.
4. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokineticspharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44:79-86.
5. Pasipanodya J, Gumbo T. An oracle: antituberculosis pharmacokineticspharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob Agents Chemother 2011; 55:24-34.
6. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013; 208:1464-73.
7. Gumbo T, Louie A, Deziel MR, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007; 51:3781-8.
8. Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003; 47:2118-24.
9. Gumbo T, Louie A, Liu W, et al. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother 2007; 51:2329-36.
10. Gumbo T, Siyambalapitiyage Dona CS, Meek C, Leff R. Pharmacokinetics-Pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: A paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 2009; 53:3197-204.
11. Srivastava S, Musuka S, Sherman C, Meek C, Leff R, Gumbo T. Effluxpump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis 2010; 201:1225-31.
12. Gumbo T, Louie A, Liu W, et al. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J Infect Dis 2007; 195:194-201.
13. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121:939-49.
14. Sirgel FA, Donald PR, Odhiambo J, et al. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother 2000; 45:859-70.
15. Vall-Spinosa A, Lester W, Moulding T, Davidson PT, McClatchy JK. Rifampin in the treatment of drug-resistant Mycobacterium tuberculosis infections. N Engl J Med 1970; 283:616-21.
16. Selkon JB, Devadatta S, Kulkarni KG, et al. The emergence of isoniazid-resistant cultures in patients with pulmonary tuberculosis during treatment with isoniazid alone or isoniazid plus PAS. Bull World Health Organ 1964; 31:273-994.
17. Yeager RL, Munroe WG, Dessau FI. Pyrazinamide (aldinamide. in the treatment of pulmonary tuberculosis. Am Rev Tuberc 1952; 65: 523-46.
18. Ginsburg AS, Woolwine SC, Hooper N, et al. The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med 2003; 349:1977-8.
19. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004; 190: 1642-51.
20. Gumbo T, Louie A, Deziel MR, Drusano GL. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. Antimicrob Agents Chemother 2005; 49:3178-81.
21. Jindani A, Dore CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003; 167:1348-54.
22. Kubendiran G, Paramasivan CN, Sulochana S, Mitchison DA. Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis. J Chemother 2006; 18:617-23.
23. Wilkins JJ, Langdon G, McIlleron H, Pillai GC, Smith PJ, Simonsson US. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. Eur J Clin Pharmacol 2006; 62:727-35.
24. Conte JE Jr, Golden JA, Duncan S, McKenna E, Zurlinden E. Intrapulmonary concentrations of pyrazinamide. Antimicrob Agents Chemother 1999; 43:1329-33.
25. Chigutsa E, Pasipanodya JG, Visser ME, et al. The impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob Agents Chemother 2015; 59:38-45.
26. Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996; 64:2062-9.
27. Drusano GL, Sgambati N, Eichas A, Brown DL, Kulawy R, Louie A. The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection Model. MBio 2010; 1.
28. Schmalstieg AM, Srivastava S, Belkaya S, et al. The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. Antimicrob Agents Chemother 2012; 56:4806-15.
29. Srivastava S, Gumbo T. In vitro and in vivo modeling of anti-tuberculosis drugs and its impact on optimization of doses and regimens. Curr Pharm Des 2011; 17:2881-8.
30. Srivastava S, Sherman C, Meek C, Leff R, Gumbo T. Pharmacokinetic mismatch does not lead to emergence of isoniazid-or rifampinresistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling. Antimicrob Agents Chemother 2011; 55:5085-9.
31. Musuka S, Srivastava S, Siyambalapitiyage Dona CW, et al. Thioridazine pharmacokinetic-pharmacodynamic parameters "wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners. Antimicrob Agents Chemother 2013; 57:5870-7.
32. Drusano GL, Sgambati N, Eichas A, Brown D, Kulawy R, Louie A. Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system. MBio 2011; 2.
33. Ginsburg AS, Lee J, Woolwine SC, Grosset JH, Hamzeh FM, Bishai WR. Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system. Antimicrob Agents Chemother 2005; 49:853-6.
34. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrugresistant tuberculosis not due to noncompliance but to betweenpatient pharmacokinetic variability. J Infect Dis 2011; 204:1951-9.
35. Pasipanodya JG, Srivastava S, Gumbo T. Acquired drug resistance because of pharmacokinetic variability in a young child with tuberculosis. Pediatr Infect Dis J 2014; 33:1205.
36. Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 2012; 55:169-77.
37. Pasipanodya JG, Gumbo T. A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients. Clin Infect Dis 2013; 57:21-31.
38. European Medicines Agency. Qualification opinion: In vitro hollow fiber system model of tuberculosis (HFS-TB), 2015. http://www.ema. europa.eu/docs/en-GB/document-library/Regulatory-and-procedural-guideline/2015/02/WC500181899.pdf. Accessed 8 April 2015.
39. Nuermberger E. Using animal models to develop new treatments for tuberculosis. Semin Respir Crit Care Med 2008; 29:542-51.
40. Lenaerts AJ, Degroote MA, Orme IM. Preclinical testing of new drugs for tuberculosis: current challenges. Trends Microbiol 2008; 16:48-54.
41. Hoff DR, Ryan GJ, Driver ER, et al. Location of intra-and extracellular M. tuberculosis populations in lungs of mice and Guinea pigs during disease progression and after drug treatment. PLoS One 2011; 6: e17550.
42. Grosset J. Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrob Agents Chemother 2003; 47:833-6.
43. Ahmad Z, Klinkenberg LG, Pinn ML, et al. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the Guinea pig. J Infect Dis 2009; 200: 1136-43.
44. Eum SY, Kong JH, Hong MS, et al. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 2010; 137:122-8.
45. Lecoeur HF, Lagrange PH, Truffot-Pernot C, Gheorghiu M, Grosset J. Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice. Clin Exp Immunol 1989; 76:458-62.
46. Medina E, North RJ. Resistance ranking of some common inbred mouse strains to Mycobacterium tuberculosis and relationship to major histocompatibility complex haplotype and Nramp1 genotype. Immunology 1998; 93:270-4.
47. Driver ER, Ryan GJ, Hoff DR, et al. Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012; 56:3181-95.
48. Pan H, Yan BS, Rojas M, et al. Ipr1 gene mediates innate immunity to tuberculosis. Nature 2005; 434:767-72.
49. Rosenthal IM, Tasneen R, Peloquin CA, et al. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother 2012; 56: 4331-40.
50. Harper J, Skerry C, Davis SL, et al. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis 2012; 205:595-602.
51. Kramnik I, Dietrich WF, Demant P, Bloom BR. Genetic control of resistance to experimental infection with virulent Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2000; 97:8560-5.
52. Pichugin AV, Yan BS, Sloutsky A, Kobzik L, Kramnik I. Dominant role of the sst1 locus in pathogenesis of necrotizing lung granulomas during chronic tuberculosis infection and reactivation in genetically resistant hosts. Am J Pathol 2009; 174:2190-201.
53. Ordonez AA, Pokkali S, DeMarco VP, et al. Radioiodo-DPA-713 imaging correlates with bactericidal activity of tuberculosis treatments in mice. Antimicrob Agents Chemother 2015; 59:642-9.
54. Davis SL, Be NA, Lamichhane G, et al. Bacterial thymidine kinase as a non-invasive imaging reporter for Mycobacterium tuberculosis in live animals. PLoS One 2009; 4:e6297.
55. Irwin SM, Gruppo V, Brooks E, et al. Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas. Antimicrob Agents Chemother 2014; 58:4026-34.
56. Lanoix J, Lenaerts AJ, Nuermberger EL. Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis. Dis Model Mech 2015. In press.
57. Feldman WH, Karlson AG, Hinshaw HC. Para-aminosalicylic acid in experimental tuberculosis in Guinea pigs. Proc Staff Meet Mayo Clin 1947; 22:473-9.
58. Feldman WH, Karlson AG, Hinshaw HC. Streptomycin in experimental tuberculosis: the effects in Guinea pigs following infection in intravenous inoculation. Am Rev Tuberc 1947; 56:346-59.
59. Feldman WH, Hinshaw HC, Karlson AG. Frequency of administration of streptomycin; its influence on results of treatment of tuberculosis in Guinea pigs. Am Rev Tuberc 1947; 55:435-43.
60. Karlson AG, Feldman WH. The effect of combined therapy with isoniazid and streptomycin on experimental tuberculosis of Guinea pigs. Am Rev Tuberc 1953; 68:575-83.
61. Karlson AG, Feldman WH. The use of Guinea pigs in studying chemotherapy of experimental tuberculosis. Ann N Y Acad Sci 1949; 52:637-45.
62. McCune RM, Feldmann FM, Lambert HP, McDermott W. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J Exp Med 1966; 123:445-68.
63. McCune RM, Feldmann FM, McDermottW. Microbial persistence. II. Characteristics of the sterile state of tubercle bacilli. J Exp Med 1966; 123:469-86.
64. Ordway DJ, Shanley CA, Caraway ML, et al. Evaluation of standard chemotherapy in the Guinea pig model of tuberculosis. Antimicrob Agents Chemother 2010; 54:1820-33.
65. Hoff DR, Caraway ML, Brooks EJ, et al. Metronidazole lacks antibacterial activity in Guinea pigs infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother 2008; 52:4137-40.
66. Ahmad Z, Nuermberger EL, Tasneen R, et al. Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and Guinea pig. J Antimicrob Chemother 2010; 65:729-34.
67. Shang S, Shanley CA, Caraway ML, et al. Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in Guinea pigs. Antimicrob Agents Chemother 2011; 55:124-31.
68. Ahmad Z, Fraig MM, Pinn ML, et al. Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models. J Antimicrob Chemother 2011; 66: 1560-6.
69. Dutta NK, Illei PB, Peloquin CA, et al. Rifapentine is not more active than rifampin against chronic tuberculosis in Guinea pigs. Antimicrob Agents Chemother 2012; 56:3726-31.
70. Lenaerts AJ, Hoff D, Aly S, et al. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob Agents Chemother 2007; 51:3338-45.
71. Ryan GJ, Hoff DR, Driver ER, et al. Multiple M. tuberculosis phenotypes in mouse and Guinea pig lung tissue revealed by a dual-staining approach. PLoS One 2010; 5:e11108.
72. Dutta NK, Alsultan A, Gniadek TJ, et al. Potent rifamycin-sparing regimen cures Guinea pig tuberculosis as rapidly as the standard regimen. Antimicrob Agents Chemother 2013; 57:3910-6.
73. Sugawara I, Yamada H, Mizuno S. Nude rat (F344/N-rnu. tuberculosis. Cell Microbiol 2006; 8:661-7.
74. Sugawara I, Yamada H, Mizuno S. Pathological and immunological profiles of rat tuberculosis. Int J Exp Pathol 2004; 85:125-34.
75. Heng Y, Seah PG, Siew JY, et al. Mycobacterium tuberculosis infection induces hypoxic lung lesions in the rat. Tuberculosis (Edinb) 2011; 91:339-41.
76. Singhal A, Aliouat EM, Herve M, et al. Experimental tuberculosis in the Wistar rat: a model for protective immunity and control of infection. PLoS One 2011; 6:e18632.
77. Chatterji M, Shandil R, Manjunatha MR, et al. 1, 4-azaindole, a potential drug candidate for treatment of tuberculosis. Antimicrob Agents Chemother 2014; 58:5325-31.
78. Kumar N, Vishwas KG, Kumar M, et al. Pharmacokinetics and dose response of anti-TB drugs in rat infection model of tuberculosis. Tuberculosis (Edinb) 2014; 94:282-6.
79. Elwood RL, Wilson S, Blanco JC, et al. The American cotton rat: a novel model for pulmonary tuberculosis. Tuberculosis (Edinb) 2007; 87:145-54.
80. McFarland CT, Ly L, Jeevan A, et al. BCG vaccination in the cotton rat (Sigmodon hispidus. infected by the pulmonary route with virulent Mycobacterium tuberculosis. Tuberculosis (Edinb) 2010; 90:262-7.
81. Dannenberg AM Jr. Roles of cytotoxic delayed-type hypersensitivity and macrophage-activating cell-mediated immunity in the pathogenesis of tuberculosis. Immunobiology 1994; 191:461-73.
82. Manabe YC, Dannenberg AM Jr, Tyagi SK, et al. Different strains of Mycobacterium tuberculosis cause various spectrums of disease in the rabbit model of tuberculosis. Infect Immun 2003; 71:6004-11.
83. Subbian S, Tsenova L, Yang G, et al. Chronic pulmonary cavitary tuberculosis in rabbits: a failed host immune response. Open Biol 2011; 1:110016.
84. Tsenova L, Ellison E, Harbacheuski R, et al. Virulence of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli. J Infect Dis 2005; 192:98-106.
85. Via LE, Schimel D, Weiner DM, et al. Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [(1)(8)F]2-fluoro-deoxy-D-glucose positron emission tomography and computed tomography. Antimicrob Agents Chemother 2012; 56:4391-402.
86. Nedeltchev GG, Raghunand TR, Jassal MS, Lun S, Cheng QJ, Bishai WR. Extrapulmonary dissemination of Mycobacterium bovis but not Mycobacterium tuberculosis in a bronchoscopic rabbit model of cavitary tuberculosis. Infect Immun 2009; 77:598-603.
87. Helke KL, Mankowski JL, Manabe YC. Animal models of cavitation in pulmonary tuberculosis. Tuberculosis (Edinb) 2006; 86:337-48.
88. Prideaux B, Dartois V, Staab D, et al. High-sensitivity MALDI-MRMMS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal Chem 2011; 83:2112-8.
89. Kjellsson MC, Via LE, Goh A, et al. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother 2012; 56:446-57.
90. Via LE, Lin PL, Ray SM, et al. Tuberculous granulomas are hypoxic in Guinea pigs, rabbits, and nonhuman primates. Infect Immun 2008; 76:2333-40.
91. Gardner MB, Luciw PA.Macaque models of human infectious disease. ILAR J 2008; 49:220-55.
92. Lin PL, Pawar S, Myers A, et al. Early events in Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun 2006; 74:3790-803.
93. Flynn JL. Lessons from experimental Mycobacterium tuberculosis infections. Microbes Infect 2006; 8:1179-88.
94. Schmidt LH. Studies on the antituberculous activity of ethambutol in monkeys. Ann N Y Acad Sci 1966; 135:747-58.
95. Lin PL, Coleman T, Carney JP, et al. Radiologic responses in cynomolgous macaques for assessing tuberculosis chemotherapy regimens. Antimicrob Agents Chemother 2013; 57:4237-44.
96. Lin PL, Dartois V, Johnston PJ, et al. Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc Natl Acad Sci USA 2012; 109:14188-93.
97. Carroll MW, Jeon D, Mountz JM, et al. Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2013; 57:3903-9.
98. Via LE, Weiner DM, Schimel D, et al. Differential virulence and disease progression following Mycobacterium tuberculosis complex infection of the common marmoset (Callithrix jacchus). Infect Immun 2013; 81:2909-19.
99. Franzblau SG, Degroote MA, Cho SH, et al. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis (Edinb) 2012; 92:453-88.
100. Ioerger TR, Feng Y, Ganesula K, et al. Variation among genome sequences of H37Rv strains of Mycobacterium tuberculosis from multiple laboratories. J Bacteriol 2010; 192:3645-53.
101. Cooper AM. T cells in mycobacterial infection and disease. Curr Opin Immunol 2009; 21:378-84.
102. Ordway D, Palanisamy G, Henao-Tamayo M, et al. The cellular immune response to Mycobacterium tuberculosis infection in the Guinea pig. J Immunol 2007; 179:2532-41.
103. De Groote MA, Gilliland JC, Wells CL, et al. Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011; 55:1237-47.
104. Tasneen R, Li SY, Peloquin CA, et al. Sterilizing activity of novel TM. Antimicrob Agents Chemother 2011; 55:5485-92.
105. De Steenwinkel JE, Ten Kate MT, de Knegt GJ, et al. Course of murine tuberculosis and response to first-line therapy depends on route of infection and inoculum size. Int J Tuberc Lung Dis 2011; 15: 1478-84.
106. Andries K, Gevers T, Lounis N. Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis. Antimicrob Agents Chemother 2010; 54:4540-4.
107. Cooper AM, Callahan JE, Keen M, Belisle JT, Orme IM. Expression of memory immunity in the lung following re-exposure to Mycobacterium tuberculosis. Tuber Lung Dis 1997; 78:67-73.
108. Rosenthal IM, Williams K, Tyagi S, et al. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med 2006; 174:94-101.
109. Nuermberger E. The role of the mouse model in the evaluation of new anti-tuberculosis drugs. Prog Respir Research 2011; 40:145-52.
110. Munoz-Elias EJ, Timm J, Botha T, Chan WT, Gomez JE, McKinney JD. Replication dynamics of Mycobacterium tuberculosis in chronically infected mice. Infect Immun 2005; 73:546-51.
111. Gill WP, Harik NS, Whiddon MR, Liao RP, Mittler JE, Sherman DR. A replication clock for Mycobacterium tuberculosis. Nat Med 2009; 15:211-4.
112. McCune RM, Tompsett R. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy. J Exp Med 1956; 104: 737-62.
113. Grumbach F, Canetti G, Le LM. Durable character of the sterilization of experimental tuberculosis in mice by rifampicin-isoniazid association: cortisone test. Rev Tuberc Pneumol (Paris) 1970; 34: 312-9.
114. Ji B, Lounis N, Truffot-Pernot C, Grosset J. Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. Antimicrob Agents Chemother 1994; 38:2521-9.
115. Lounis N, Gevers T, Van den Berg J, Verhaeghe T, van HR, Andries K. Prevention of drug carryover effects in studies assessing antimycobacterial efficacy of TMC207. J Clin Microbiol 2008; 46:2212-5.
116. Williams K, Minkowski A, Amoabeng O, et al. Sterilizing activities of novel combinations lacking first-and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2012; 56: 3114-20.
117. Veziris N, Truffot-Pernot C, Aubry A, Jarlier V, Lounis N. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 2003; 47:3117-22.
118. Zhang M, Li SY, Rosenthal IM, et al. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. Am J Respir Crit Care Med 2011; 183:1254-61.
119. Zhang T, Li SY, Williams KN, Andries K, Nuermberger EL. Shortcourse chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med 2011; 184:732-7.
120. Zhang T, Zhang M, Rosenthal IM, Grosset JH, Nuermberger EL. Shortcourse therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med 2009; 180:1151-7.
121. Grumbach F, Canetti G, Grosset J, Le LM. Late results of long-term intermittent chemotherapy of advanced, murine tuberculosis: limits of the murine model. Tubercle 1967; 48:11-26.
122. Grosset J, Truffot C, Fermanian J, Lecoeur H. Sterilizing activity of the main drugs on the mouse experimental tuberculosis. Pathol Biol (Paris) 1982; 30:444-8.
123. Grosset J. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Bull Int Union Tuberc 1978; 53:5-12.
124. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3:S231-79.
125. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacincontaining regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 2004; 170:1131-4.
126. Ibrahim M, Truffot-Pernot C, Andries K, Jarlier V, Veziris N. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am J Respir Crit Care Med 2009; 180:553-7.
127. Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014; 371:1577-87.
128. Rosenthal IM, Zhang M, Almeida D, Grosset JH, Nuermberger EL. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am J Respir Crit Care Med 2008; 178:989-93.
129. Dorman SE, Goldberg S, Stout JE, et al. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis 2012; 206:1030-40.
130. Nuermberger E, Tyagi S, Tasneen R, et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 2008; 52:1522-4.
131. Anonymous. Long-term chemotherapy in the treatment of chronic pulmonary tuberculosis with cavitation: A report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee. Tubercle 1962; 63:201-67.
132. Lenaerts AM, Chase SE, Chmielewski AJ, Cynamon MH. Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice. Antimicrob Agents Chemother 1999; 43:2356-60.
133. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380:986-93.
134. Dawson R, Diacon AH, Everitt D, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drugsusceptible or drug-resistant pulmonary tuberculosis. Lancet 2015. In press.
135. Li S, Irwin SM, Converse PJ, Mdluli KE, Lenaerts AJ, Nuermberger EL. Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models. Antimicrob Agents Chemother 2014. In press.